Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

Peter C Fong; Timothy A Yap; David S Boss; Craig P Carden; Marja Mergui-Roelvink; Charles Gourley; Jacques De Greve; Jan Lubinski; Susan Shanley; Christina Messiou; Roger A'Hern; Andrew Tutt; Alan Ashworth; John Stone; James Carmichael; Jan H M Schellens; Johann S de Bono; Stan B Kaye

doi:10.1200/JCO.2009.26.9589

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

Peter C Fong, Timothy A Yap, David S Boss, Craig P Carden, Marja Mergui-Roelvink, Charles Gourley, Jacques De Greve, Jan Lubinski, Susan Shanley, Christina Messiou, Roger A'Hern, Andrew Tutt, Alan Ashworth, John Stone, James Carmichael, Jan H M Schellens, Johann S de Bono, Stan B Kaye

Research output: Contribution to journal › Article › peer-review

Abstract / Description of output

Selective tumor cell cytotoxicity can be achieved through a synthetic lethal strategy using poly(ADP)-ribose polymerase (PARP) inhibitor therapy in BRCA1/2 mutation carriers in whom tumor cells have defective homologous recombination (HR) DNA repair. Platinum-based chemotherapy responses correlate with HR DNA repair capacity. Olaparib is a potent, oral PARP inhibitor that is well tolerated, with antitumor activity in BRCA1/2 mutation carriers.

Original language	English
Pages (from-to)	2512-9
Number of pages	8
Journal	Journal of Clinical Oncology
Volume	28
Issue number	15
DOIs	https://doi.org/10.1200/JCO.2009.26.9589
Publication status	Published - 2010

Access to Document

10.1200/JCO.2009.26.9589

Cite this

Fong, P. C., Yap, T. A., Boss, D. S., Carden, C. P., Mergui-Roelvink, M., Gourley, C., De Greve, J., Lubinski, J., Shanley, S., Messiou, C., A'Hern, R., Tutt, A., Ashworth, A., Stone, J., Carmichael, J., Schellens, J. H. M., de Bono, J. S., & Kaye, S. B. (2010). Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. Journal of Clinical Oncology, 28(15), 2512-9. https://doi.org/10.1200/JCO.2009.26.9589

@article{168fe3e70a444b7891cdcac3198cc9cd,

title = "Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval",

abstract = "Selective tumor cell cytotoxicity can be achieved through a synthetic lethal strategy using poly(ADP)-ribose polymerase (PARP) inhibitor therapy in BRCA1/2 mutation carriers in whom tumor cells have defective homologous recombination (HR) DNA repair. Platinum-based chemotherapy responses correlate with HR DNA repair capacity. Olaparib is a potent, oral PARP inhibitor that is well tolerated, with antitumor activity in BRCA1/2 mutation carriers.",

author = "Fong, {Peter C} and Yap, {Timothy A} and Boss, {David S} and Carden, {Craig P} and Marja Mergui-Roelvink and Charles Gourley and {De Greve}, Jacques and Jan Lubinski and Susan Shanley and Christina Messiou and Roger A'Hern and Andrew Tutt and Alan Ashworth and John Stone and James Carmichael and Schellens, {Jan H M} and {de Bono}, {Johann S} and Kaye, {Stan B}",

year = "2010",

doi = "10.1200/JCO.2009.26.9589",

language = "English",

volume = "28",

pages = "2512--9",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "15",

}

Fong, PC, Yap, TA, Boss, DS, Carden, CP, Mergui-Roelvink, M, Gourley, C, De Greve, J, Lubinski, J, Shanley, S, Messiou, C, A'Hern, R, Tutt, A, Ashworth, A, Stone, J, Carmichael, J, Schellens, JHM, de Bono, JS & Kaye, SB 2010, 'Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval', Journal of Clinical Oncology, vol. 28, no. 15, pp. 2512-9. https://doi.org/10.1200/JCO.2009.26.9589

TY - JOUR

T1 - Poly(ADP)-ribose polymerase inhibition

T2 - frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

AU - Fong, Peter C

AU - Yap, Timothy A

AU - Boss, David S

AU - Carden, Craig P

AU - Mergui-Roelvink, Marja

AU - Gourley, Charles

AU - De Greve, Jacques

AU - Lubinski, Jan

AU - Shanley, Susan

AU - Messiou, Christina

AU - A'Hern, Roger

AU - Tutt, Andrew

AU - Ashworth, Alan

AU - Stone, John

AU - Carmichael, James

AU - Schellens, Jan H M

AU - de Bono, Johann S

AU - Kaye, Stan B

PY - 2010

Y1 - 2010

N2 - Selective tumor cell cytotoxicity can be achieved through a synthetic lethal strategy using poly(ADP)-ribose polymerase (PARP) inhibitor therapy in BRCA1/2 mutation carriers in whom tumor cells have defective homologous recombination (HR) DNA repair. Platinum-based chemotherapy responses correlate with HR DNA repair capacity. Olaparib is a potent, oral PARP inhibitor that is well tolerated, with antitumor activity in BRCA1/2 mutation carriers.

AB - Selective tumor cell cytotoxicity can be achieved through a synthetic lethal strategy using poly(ADP)-ribose polymerase (PARP) inhibitor therapy in BRCA1/2 mutation carriers in whom tumor cells have defective homologous recombination (HR) DNA repair. Platinum-based chemotherapy responses correlate with HR DNA repair capacity. Olaparib is a potent, oral PARP inhibitor that is well tolerated, with antitumor activity in BRCA1/2 mutation carriers.

U2 - 10.1200/JCO.2009.26.9589

DO - 10.1200/JCO.2009.26.9589

M3 - Article

C2 - 20406929

SN - 0732-183X

VL - 28

SP - 2512

EP - 2519

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 15

ER -

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

Abstract / Description of output

Access to Document

Fingerprint

Cite this